FY2026 Earnings Estimate for Corcept Therapeutics Incorporated (NASDAQ:CORT) Issued By Zacks Research

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at Zacks Research lifted their FY2026 earnings per share estimates for shares of Corcept Therapeutics in a note issued to investors on Wednesday, September 25th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings of $2.11 per share for the year, up from their prior estimate of $2.09. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.12 per share.

CORT has been the subject of several other research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $38.00 price objective on shares of Corcept Therapeutics in a report on Tuesday, July 30th. HC Wainwright boosted their price objective on Corcept Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. Piper Sandler boosted their price objective on Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, September 18th. Finally, Truist Financial upped their price target on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a report on Monday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $56.50.

Corcept Therapeutics Stock Up 1.0 %

Shares of CORT stock opened at $46.75 on Monday. The stock has a market cap of $4.87 billion, a PE ratio of 44.10 and a beta of 0.45. The business has a 50-day simple moving average of $36.63 and a 200-day simple moving average of $30.93. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $47.71.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Monday, July 29th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.09. The business had revenue of $163.80 million during the quarter, compared to analysts’ expectations of $155.14 million. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The company’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.25 EPS.

Insider Buying and Selling

In related news, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total value of $509,080.00. Following the completion of the transaction, the insider now owns 22,772 shares of the company’s stock, valued at approximately $1,053,888.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Corcept Therapeutics news, insider William Guyer sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $35.30, for a total transaction of $353,000.00. Following the completion of the sale, the insider now directly owns 6,039 shares in the company, valued at approximately $213,176.70. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total value of $509,080.00. Following the completion of the sale, the insider now owns 22,772 shares of the company’s stock, valued at $1,053,888.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,251 shares of company stock valued at $1,365,292. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of large investors have recently made changes to their positions in CORT. Norden Group LLC purchased a new stake in shares of Corcept Therapeutics in the first quarter valued at approximately $50,081,000. Norges Bank acquired a new position in Corcept Therapeutics in the fourth quarter valued at approximately $24,603,000. Jacobs Levy Equity Management Inc. acquired a new position in Corcept Therapeutics in the first quarter valued at approximately $18,426,000. Jupiter Asset Management Ltd. lifted its holdings in Corcept Therapeutics by 1,149.0% in the first quarter. Jupiter Asset Management Ltd. now owns 744,469 shares of the biotechnology company’s stock valued at $18,753,000 after acquiring an additional 684,863 shares during the last quarter. Finally, Clearbridge Investments LLC acquired a new position in Corcept Therapeutics in the first quarter valued at approximately $14,670,000. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.